Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
October 25, 2023
- Panel Approves Revision to Basic Blood Product Policy; Change to Take Effect Next April
October 24, 2023
- Japan PM Vows to Review Official Prices, Eyeing Wage Hikes
October 24, 2023
- Japan Panel Clears Additional Usages for Adcetris, Opdivo, and More
October 24, 2023
- PMDA’s New Mid-Term Plan to Push Pediatric, Orphan Drug Development to Counter Losses
October 23, 2023
- Japan to Continue Accepting GLP Data from UK under New Bilateral Deal: MHLW
October 23, 2023
- Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
October 23, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care
October 19, 2023
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
- Medipharma Might Face Administrative Penalty over Trial Data Tampering
October 18, 2023
- Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
- AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
- MHLW Sets Up Hotline for Production Site Change for Supply-Crippled Drugs
October 17, 2023
- Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
- MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
- Japan’s New Economic Package to Include Dementia Measures: PM
October 16, 2023
- Xarelto’s Label Expansion Up for Japan Panel Review on Oct. 27
October 16, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…